Pacira BioSciences Inc (PCRX)
29.37
-0.49
(-1.64%)
USD |
NASDAQ |
May 10, 16:00
29.37
0.00 (0.00%)
After-Hours: 20:00
Pacira BioSciences Accounts Receivable (Quarterly): 101.64M for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 101.64M |
December 31, 2023 | 105.56M |
September 30, 2023 | 96.96M |
June 30, 2023 | 99.08M |
March 31, 2023 | 93.20M |
December 31, 2022 | 98.40M |
September 30, 2022 | 93.47M |
June 30, 2022 | 91.10M |
March 31, 2022 | 92.10M |
December 31, 2021 | 96.32M |
September 30, 2021 | 49.98M |
June 30, 2021 | 68.36M |
March 31, 2021 | 52.58M |
December 31, 2020 | 53.05M |
September 30, 2020 | 46.14M |
June 30, 2020 | 44.01M |
March 31, 2020 | 38.99M |
December 31, 2019 | 47.53M |
September 30, 2019 | 42.57M |
June 30, 2019 | 41.15M |
March 31, 2019 | 39.77M |
December 31, 2018 | 38.00M |
September 30, 2018 | 34.27M |
June 30, 2018 | 35.64M |
March 31, 2018 | 31.20M |
Date | Value |
---|---|
December 31, 2017 | 31.66M |
September 30, 2017 | 27.02M |
June 30, 2017 | 27.47M |
March 31, 2017 | 27.70M |
December 31, 2016 | 29.94M |
September 30, 2016 | 26.76M |
June 30, 2016 | 28.65M |
March 31, 2016 | 25.90M |
December 31, 2015 | 25.86M |
September 30, 2015 | 25.92M |
June 30, 2015 | 24.28M |
March 31, 2015 | 24.51M |
December 31, 2014 | 22.37M |
September 30, 2014 | 20.52M |
June 30, 2014 | 20.54M |
March 31, 2014 | 15.97M |
December 31, 2013 | 14.59M |
September 30, 2013 | 9.771M |
June 30, 2013 | 7.756M |
March 31, 2013 | 5.243M |
December 31, 2012 | 4.352M |
September 30, 2012 | 2.459M |
June 30, 2012 | 3.214M |
March 31, 2012 | 0.86M |
December 31, 2011 | 2.113M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
38.99M
Minimum
Mar 2020
105.56M
Maximum
Dec 2023
72.61M
Average
79.73M
Median
Accounts Receivable (Quarterly) Benchmarks
Dynavax Technologies Corp | 40.61M |
Arbutus Biopharma Corp | 2.139M |
Chimerix Inc | 0.001M |
Karyopharm Therapeutics Inc | 26.96M |
FibroGen Inc | 37.08M |